Chapter 4 · Management
Two drugs,
two approvals.
Track record.
In biotech, you mostly bet on whether a team can execute the trial-to-market gauntlet. This one has.
↓ scroll to read
✦ The bottom line
Most biotechs never get a single drug approved. Insmed's long-tenured leadership has steered two through development, FDA approval, and commercial launch — Arikayce and now Brinsupri. That demonstrated ability to execute is the most important management signal in this industry.
↓ the brief below
✦ Teach me
Why execution track record is everything
In a profitable company you judge management on margins and capital allocation. In a pre-profit biotech, you mostly judge them on one question: can they get drugs through trials and onto the market? The failure rate is brutal — most candidates never make it.
A team that has repeatedly done it — designed successful trials, won approvals, built a salesforce — has shown the rarest and most valuable skill in the field. That's the bet you're making on Insmed's leadership.
Wall Street calls this
Execution / R&D track record
Past approvals don't guarantee the next one — but a proven team meaningfully shifts the odds in an industry where most companies never ship a single product.